Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

June 15, 2017

37% of Those Who Received CTL019 in Phase 2 Clinical Trial Had Their Lymphoma Disappear

News

Thirty-seven percent of patients with a difficult-to-treat lymphoma had their cancer disappear after receiving Novartis’ CTL019 (tisagenlecleucel), according to an interim analysis of Phase 2 clinical trial results. Other patients achieved ... Read more

May 17, 2017May 19, 2017

Lymphoma Patients with High-risk Mutation Respond Better to Imbruvica Than Those Without Mutation

News

Patients with a certain kind of leukemia or lymphoma who carry a mutation that makes their cancer difficult to treat respond better to Pharmacyclics’ Imbruvica (ibrutinib) than people without the mutation, ... Read more

May 15, 2017

Adding Etoposide Improves Survival in Middle-aged and Older Lymphoma Patients, Study Reports

News

Adding etoposide to a treatment regimen called CHOP led to longer survival times for middle-aged and older people with a certain kind of lymphoma, a Scandinavian study reported. The results ... Read more

May 4, 2017

Nordic Nanovector to Update Data on Betalutin in Non-Hodgkin’s Lymphoma Trial at June Meeting

News

Nordic Nanovector will present new data from the Phase 1/2 trial (NCT01796171) of its investigational treatment Betalutin for relapsed or treatment-resistant non-Hodgkin’s lymphoma at the International Conference on Malignant Lymphoma, ... Read more

March 23, 2017March 23, 2017

Breast Implants Linked to Rare Lymphoma Type, According to FDA

News

Anaplastic large cell lymphoma can, in rare cases, develop in women with breast implants, according to a statement by the U.S. Food and Drug Administration (FDA). Lymphoma seems to develop ... Read more

March 7, 2017March 7, 2017

UNC Lineberger Cancer Center Launches Lymphoma Trials with CAR T-cells

News

The University of North Carolina Lineberger Comprehensive Cancer Center has launched two clinical trials exploring CAR T-cells in patients with lymphoma, making it easier for patients in the Southeast to participate in ... Read more

March 1, 2017

Letermovir Helps Prevent Post-transplant Viral Infections, Clinical Trial Shows

News

Lymphoma patients who obtain stem cell transplants may soon have a new therapy to ward off cytomegalovirus (CMV) infections, the results of a Phase 3 clinical trial indicate. In contrast ... Read more

February 21, 2017

Delivering Lymphoma Chemotherapies with Platelets Could Reduce Adverse Effects, Study Reports

News

Using blood platelets to deliver lymphoma chemotherapies could reduce adverse effects of the treatment, according to a study. The use of natural cells such as platelets also could get around ... Read more

February 16, 2017

Lymphoma Patients Respond to Pembrolizumab After Other Therapies Fail, Small Study Indicates

News

Patients with NK-cell or T-cell lymphomas whose previous treatments failed showed remarkably good responses to the immunotherapy Keytruda (pembrolizumab) in a small trial. The study, “PD1 blockade with pembrolizumab is ... Read more

February 1, 2017

Abexinostat Shows Potential as Lymphoma Treatment in European Clinical Trial

News

A clinical trial of the investigational drug abexinostat in patients with non-Hodgkin’s lymphoma or chronic lymphocytic leukemia demonstrated that the treatment may be suitable for these types of cancer, but ... Read more